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Methods: Levels of IL-18 was determined by ELISA in serum
from healthy individuals (n=31), HB-immune patients (n=13),
anti-HBe positive patients with HBV DNA levels below 104 (n=25)
or above 104 (n=20) copies/ml and HBeAg positive patients with
chronic hepatitis B (CHB) (n=14). HBV DNA was assessed by Cobas
Amplicor HBV Monitor TM test. IL-18 reactivity was monitored
longitudinally in comparison with the viremia in 15 CHB patients
treated with interferon-alpha.
Results: The serum levels of IL-18 was signiﬁcantly higher in anti-
HBeAg positive and HBeAg positive patients with CHB compared
with healthy individuals (p<0.05). In vivo, the longitudinal study
demonstrated a highly inverse correlation between the levels of
HBV DNA and the circulating concentrations of IL-18. Patients
with IFN alpha-induced reduction in HBV DNA levels exhibited
a signiﬁcant increase in measurable IL-18 reactivity (p<0.001)
which always peaked after the decrease of HBV DNA in serum.
Conclusions: The inverse correlation between the decrease of
HBV viremia and the increase of measurable circulatory levels
of IL-18 indicate a strong relationship between the control of
replication of HBV DNA and the production of IL-18 in CHB.
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In HBeAg positive chronic hepatitis B treatment, serum HBeAg
loss or serological conversion was primary endpoint and the most
important parameter of the efﬁcacy evaluation. But in the pa-
tients treatment with interferon and nucleoside analogues, the
change modules of serum HBV DNA, HBeAg and HBsAg contents
was difference between the two kinds of drugs. The aim of this
study was analyzing the correlation ships among serum HBV DNA,
HBeAg and HBsAg contents in HBsAg-positive chronic hepatitis B
patients treated with interferon.
There were 228 cases of HBeAg-positive patients, with serum HB-
sAg positive for more than 6 months, HBV DNA content >5.0×105
copies/ml and ALT level from 41 to 400 U/ml, enrolled in
this study. After enrolled, patients was treated with PEGASYS,
180mg, subcutaneous injection once weekly, for 48 weeks, and
with another 24 week follow. The serum HBV NDA, HBeAg and
HBsAg contents were examined at 0, 24 and 48 week and the end
of follow.
The serum HBV NDA, HBeAg and HBsAg baseline were lg
7.139±0.974 copies/ml, lg 2.486±0.926 S/CO and lg 4.139±0.756
IU/ml, respectively, and the correlation among them were sig-
niﬁcance (p<0.001), and at 24, 48 week on-treatment and the
end of follow, the correlation among them was signiﬁcance
also (p<0.001). After mixed-variable linear regression analysis
tested, at 48 week, the HBsAg clear could be predicted by the
levels of HBsAg baseline and its descend extent at 24 week, and
HBV DNA descend extent at 24 and 48 week, and the HBeAg
clear could be predicted by the levels of HBeAg baseline and its
descend extent at 24 week, and HBV DNA descend extent at 24
and 48 week.
In this study it was shown that during the course of interferon
therapy, there were correlation among HBV DNA, HBeAg and HB-
sAg contents and their changes, and it was important monitoring
the changes of them.
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Backgroud: To assess effects of combination of lamivudine plus
interferon-α for HBeAg positive chronic hepatitis B.
Methods: We included randomized trials of combination of
interferon-α plus lamivudine vs. lamivudine or interferon-α alone
in adult patients with HBeAg positive chronic hepatitis B. We
searched MEDLINE, EMBASE, and Cochrane and SCI database
(1980-2008), supplemented with reference lists and contact with
trial investigators. We used random-effect model to pool trials,
and employed a limited number of pre-speciﬁed variables to
explore sources of heterogeneity.
Results: Compared to interferon-α, combination therapy did
not improve HBeAg seroconversion (29.3% vs. 28.3%; RR1.05,
95%CI0.81 to 1.35) and combined virological response (19.9% vs.
12.9%; 1.52, 0.82 to 2.86), loss of HBV DNA (38.1% vs. 31.1%;
1.38, 1.03 to 1.84), and ALT normalization (40.0% vs. 36.8%; 1.13,
0.93 to 1.38) at the end of post-treatment follow-up. Compared
to lamivudine, combination therapy improved HBeAg seroconver-
sion (30.5% vs. 17.8%; 1.76, 1.29 to 2.42), loss of HBV DNA (32.5%
vs. 19.8%; 1.61, 1.29 to 2.02), combined virological response
(25.1% vs. 10.8%; 2.30, 1.70 to 3.12), and ALT normalization
(37.9% vs. 24.8%; 1.52, 1.25 to 1.84) at the end of follow-up.
Combination therapy reduced resistance to lamivudine at the
end of treatment (7.2% vs. 25.5%; 0.28, 0.19 to 0.40).
Conclusions: Combination therapy improves treatment effects
over lamivudine, but has no superior effects over interferon-α.
Given increased costs and adverse events, combination therapy
of lamivudine plus interferon-α is not recommended for routine
use.
OL-029 Differential effects of interferon and lamivudine
on serum HBV RNA inhibition in patients with
chronic hepatitis B
Yi-Wen Huang*,1,2, Kazuaki Chayama3,4, Masataka Tsuge3,4,
Shoichi Takahashi 3,4, Tsuyoshi Hatakeyama3,4, Hiromi Abe3,4,
Michio Imamura3,4, Jui-Ting Hu1,5, Chun-Jen Liu2,6,
Ming-Yang Lai 2,6, Pei-Jer Chen2,6, Ding-Shinn Chen2,6,
Sien-Sing Yang1,5, Jia-Horng Kao2,6. 1Liver Unit, Cathay General
Hospital Medical Center, Taipei, Taiwan; 2Division of
Gastroenterology, Department of Internal Medicine, National
Taiwan University College of Medicine and National Taiwan
University Hospital, Taipei, Taiwan; 3Department of Medicine
and Molecular Science, Division of Frontier Medical Science,
Programs for Biomedical Research, Graduate School of
Biomedical Sciences, Hiroshima University, Hiroshima, Japan;
4Liver Research Project Center, Hiroshima University,
Hiroshima, Japan; 5Faculty of Medicine, Fu-Jen Catholic
University College of Medicine, Taipei, Taiwan; 6Graduate
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Background: Serum HBVRNA is detected during lamivudine ther-
apy, its pattern in sequential therapy of interferon and lamivu-
dine is unknown.
Methods: HBVDNA and RNA were quantiﬁed by reverse transcrip-
tion of HBV nucleic acid extract and real-time PCR in 10 patients
under lamivudine or entecavir, 6 under sequential interferon and
lamivudine, and 3 under short-term lamivudine.
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Results: HBVRNA was undetectable in all patients before treat-
ment, became detectable in 15 (79%) during treatments. Among
these three groups, pretreatment HBVDNA (8.1±2.4 vs. 7.7±1.4
vs. 5.1±0.3 log copies/mL, p=0.06), treatment and follow-up
durations (45.5±2.0 vs. 49.7±5.6 vs. 48.7±6.4 weeks, p=0.32)
were comparable. HBVRNA was detectable at end of treatment
or follow-up in all monotherapy patients, but none in sequential
therapy (100% vs. 0%, p<0.001).
Fig. 1. Lamivudine monotherapy.
Conclusion: Compared to lamivudine, interferon treatment may
reduce HBVDNA replication through the inhibition of HBVRNA
replicative intermediates.
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Diseases, Capital Medical University, Beijing Ditan Hospital,
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Objectives: To investigate the genotypic resistance proﬁles in
chronic hepatitis B patients who could not achieve virological
response after > 48 weeks adefovire treatment.
Methods: Serum samples and clinical data were collected from
adefovir treated patients (10mg/d) who could not achieve vi-
rological response (HBV DNA negative by PCR assay) after >48
weeks adefovir treatment. Adefovir genotypic resistance was
detected with PCR product pyrosequencing. HBV genotypes were
identiﬁed by phylogenetic tree analysis of PCR product di-deoxy
sequencing results. Correlation between adefovir resistance and
clinical factors were analyzed.
Results: Totally 104 patients were tested. 22 patients (21.2%)
were adefovir resistance (Table 1) and 18 patients (17.4%) pa-
tients had rtA181V and/or rtA181T mutation. 21 patients had
genotype B HBV and 83 patients had genotype C. No other
Table 1. Adefovir resistance in tested non-virological response patients
Mutations Cases
rtA181T 13
rtA181V 2
rtN236T 4
rtA181T + rtN236T 2
rtA181V + rtN236T 1
Total 22
genotypes were detected. There was no statistical difference in
resistance rate between genotype B and C patients (P>0.05).
Adefovir resistance patients are more common in lamivudine
refractory patients than in nucleoside-naïve patients (P=0.012).
Conclusion: In adefovir treated patients without virologial re-
sponse, rtA181V/T is more common than rtN236T. Adefovir re-
sistance assay may be considered for those patients for possible
treatment modiﬁcation and adefovir resistances are more com-
mon in lamivudine refractory patients than in nucleoside-naïve
patients.
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OL-031 Nasal colonization and clonal transmission of
methicillin-susceptible Staphylococcus aureus in
healthy military volunteers in Beijing
F. Qu*,1, E.B. Cui 1, T.S. Guo1, H.J. Li 2, C.M. Bao1, S.M. Chen1,
L.M. Liu1, Y.L. Mao1, Y.-W. Tang2. 1302 Hospital of the People’s
Liberation Army, Beijing, China; 2Vanderbilt University Medical
Center, Nashville, TN, USA
Objectives: To study methicillin-susceptible Staphylococcus au-
reus (MSSA) nasal colonization and risk factors in volunteer
military camps.
Methods: In this cross-sectional observational study, we evalu-
ated the prevalence and antibiotic resistance of S. aureus nasal
colonization and risk factors in Chinese healthy volunteers in two
camps in the Beijing area. Pulsed-ﬁeld gel electrophoresis (PFGE)
was used to determine the epidemiologic relatedness between S.
aureus isolates.
Results: From May to July 2007, 1,043 nasal swabs were col-
lected from healthy volunteers from rural (560) and urban (484)
camps. A total of 209 S. aureus isolates were recovered and all
of them were MSSA. Statistically signiﬁcant risk factors related
to nasal MSSA colonization included younger age, higher educa-
tion, shorter stay, non-smoking, and less outside traveling based
on single- and multiple-variable analyses. Based on their PFGE
patterns, 123 MSSA isolates were determined to be epidemic,
indicating MSSA clonal transmission occurred in high frequencies.
These 123 isolates were further divided into 12 genotypes with
types I (38), II (15), III (21) and VI (16) as major genotypes.
A further study on these 90 epidemic and 83 sporadic strains
revealed that recently recruited soldiers from the urban camp
correlated with the MSSA clonal transmission.
Conclusions: Our data indicated that MSSA nasal colonization
and clonal transmission occur in high frequencies, especially in
the urban camp in healthy military volunteers in Beijing.
